Business Context and Reporting Period
The filing is PowerVerde, Inc.’s Form 10-K for the fiscal year ended December 31, 2014. The provided metadata identifies the company as 374Water Inc.; the filing itself identifies the registrant as PowerVerde, Inc. and does not explain that discrepancy.
PowerVerde was a development-stage company focused on commercializing zero-emission waste-heat and solar-thermal power systems, including the Liberator system. The natural-gas pipeline energy-recovery product line was suspended. The company had not commenced principal commercial operations and had generated no material product-sale revenue.
Financial Performance, Liquidity and Capitalization
| Metric | 2014 | 2013 | Change |
|---|---|---|---|
| Revenue | $428,747 | $359,362 | 19.3% increase |
| Gross profit | $428,747 | $359,362 | 19.3% increase |
| Research and development expense | $364,095 | $459,651 | 20.8% decrease |
| General and administrative expense | $501,706 | $844,259 | 40.6% decrease |
| Loss from operations | $(437,054) | $(944,548) | Improved |
| Interest expense | $(128,859) | $(147,161) | Improved |
| Net loss | $(565,913) | $(1,054,959) | Improved by $489,046 |
| Basic and diluted loss per share | $(0.02) | $(0.04) | Improved |
| Cash used in operating activities | $(337,480) | $(314,257) | Higher use of cash |
| Cash at year-end | $4,736 | $48,306 | Decreased by $43,570 |
All 2014 revenue consisted of Biotech IP licensing fees; the company reported no product revenue. Gross margin was 100% because no cost of goods sold was recorded in 2014. The filing does not provide a meaningful product-operating margin.
- Total assets were $327,822 at December 31, 2014, compared with $466,009 in 2013.
- Current assets were $220,486 and current liabilities were $141,906, producing reported working capital of $78,580 versus a $385,872 deficit in 2013.
- Total liabilities were $516,141, including $374,235 of long-term notes payable to related parties and $100,006 of accounts payable and accrued expenses.
- Stockholders’ equity was negative $188,319, compared with negative $55,671 in 2013.
- Common shares outstanding increased to 31,750,106 from 27,600,106, primarily from 4,150,000 shares issued in 2014 private placements.
- The company raised $415,000 of gross equity proceeds during 2014 and paid $7,500 of stock issuance costs. It also paid $100,000 of related-party debt.
Material Changes Versus the Prior Comparable Period
- Licensing revenue increased by $69,385, but remained unrelated to commercial sales of the company’s power systems.
- Operating expenses declined by $438,109, reflecting cash constraints and reduced use of third-party consultants.
- Net loss narrowed substantially, although the company remained unprofitable and cash flow negative.
- The maturity of approximately $400,000 of secured notes was extended to December 31, 2016. Related warrants were modified, including lower exercise prices and later expiration dates.
- Newton Investments terminated the 10-year European manufacturing and distribution license in August 2014 after the system failed to demonstrate sufficient continuous operating capacity. Newton had not sold any systems.
- Warrants outstanding declined from 7,586,000 to 5,586,000, primarily because 2,000,000 warrants expired.
Guidance, Outlook, Risks and Unusual Items
Management stated that it expected to complete development and testing of the Liberator waste-heat system during 2015 and target a market-ready system by year-end. Management also expected 2015 Biotech IP revenue to exceed 2014 levels. These are forward-looking statements, and the filing provides no firm sales guidance or assurance that either objective will be achieved.
- The company stated that it had cash sufficient to finance operations for approximately two months as of the filing date and needed to promptly raise substantial additional capital. Management warned that failure to obtain financing could force the company to cease operations.
- The independent auditor reported substantial doubt about the company’s ability to continue as a going concern, citing the 2014 net loss, accumulated deficit of $11,232,677, recurring operating losses and negative operating cash flows.
- Commercial viability remains unproven because the systems had not achieved the targeted 25,000 hours of continuous operation. There can be no assurance that technical problems will be resolved or that the products will become commercially viable.
- Lower oil and natural-gas prices since mid-2014 adversely affected the competitive position of the company’s renewable-energy products.
- Key risks include dependence on additional financing, limited operating history, intense competition, uncertain patent protection, dependence on key personnel, government incentives and regulatory approvals, supplier availability, product liability and potential shareholder dilution.
- The company used a 5,000-square-foot facility owned by a former director without a signed lease and without rent being charged since July 2013.
- A former chief technical officer’s litigation was settled in May 2014 for $30,088; all payments had been made and the case was concluded.
- The company had $5,841,620 of federal net operating loss carryforwards, but a full valuation allowance was recorded against deferred tax assets.
- Management concluded that disclosure controls and internal control over financial reporting were effective; the auditor did not provide an attestation report on internal control.
Most Important Facts an Investor Should Verify
- Confirm the issuer’s identity and whether the filing relates to 374Water Inc. or PowerVerde, Inc.
- Verify the going-concern disclosure, current cash position, subsequent financing and whether operations continued beyond the approximately two-month liquidity estimate.
- Determine the status and collectability of the $189,220 accounts receivable and the expected timing and sustainability of Biotech IP licensing revenue.
- Review the amended secured notes, related-party debt, interest obligations and warrant modifications through the December 31, 2016 maturity.
- Validate the Liberator system’s testing results, continuous-operation performance, commercialization timetable and customer or distribution commitments.
- Assess dilution from the 31.75 million shares outstanding, 5.586 million warrants and 2.75 million options.
- Confirm whether the Newton license termination, patent status, facility access and other contingencies changed after the filing date.